Skip to main content
OpenTrials
Completed

NCT Number: NCT03847220

Study of the Utility of the BOMET-QOL Questionnaire Patients With Breast Cancer and Bone Metastasis

Epidemiological, prospective and multicenter study to evaluate the utility of the BOMET-QoL questionnaire in patients with breast cancer (BC) and bone metastases (BM).

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

Female

Study type

Observational

Primary location

Hospital Universitario Virgen Del Rocío, Seville, Andalusia, Spain

Loading trial locations.

About this study

Population: Patients over 18 with breast cancer and bone metastasis.

Inclusion criteria

  • Patient over 18 years of age.
  • Patient diagnosed with breast cancer (BC) and bone metastases (BM).
  • Patient who has granted informed consent in writing to participate in the study.
  • Patient capable of understanding and completing the questionnaires.

Exclusion criteria

  • Patient with another type of disease that, in the investigator's opinion, could mask the study results.
  • Patients with a life expectancy of less than 8 months.
  • Patient who is participating in a clinical trial with an unregistered drug at the start of the study.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient over 18 years of age.
  • Patient diagnosed with BC and BM.
  • Patient who has granted informed consent in writing to participate in the study.
  • Patient capable of understanding and completing the questionnaires

Exclusion criteria

  • Patient with another type of disease that, in the investigator's opinion, could mask the study results.
  • Patients with a life expectancy of less than 8 months.
  • Patient who is participating in a clinical trial with an unregistered drug at the start of the study.

Treatment and study plan

BOMET-QoL questionnaire

Diagnostic Test

study to evaluate the utility of the BOMET-QoL questionnaire in patients with BC and BM

Primary outcomes

  1. Impact on the HRQoL

    Time frame: Up to 24 months

    Impact on the HRQoL of patients with BC and BM will be measured by the BOMET-QoL questionnaire in the context of normal clinical practice. The questionnaire will be administered to patients in each study visit from baseline visit to the final visit at 24 months. The score of the questionnaire will be measured as: Score: 0 - Always, 1 - Nearly always, 2 - Sometimes, 3 - Rarely, 4 - Never, were never is the best option and always means patient has a bad health condition.

Secondary outcomes

  1. Measurement properties of the BOMET-QoL questionnaire: validity

    Time frame: Up to 24 months

    Its cross-sectional validity will be evaluated by analysing the relationship between the BOMET-QoL scores and different clinical variables (presence of Skeleton-Related Event (SREs), symptoms and Eastern Cooperative Oncology Group (ECOG) index). The relationship between the pain VAS score and the question about state of health perceived by patient with HRQoL according to BOMET-QoL will be analysed.

  2. Measurement properties of the BOMET-QoL questionnaire: feasibility

    Time frame: Up to 24 months

    BOMET-QoL will be considered rapidly completed if patients complete questionnaire in less than 10 minutes.

  3. Measurement properties of the BOMET-QoL questionnaire: sensitivity to change

    Time frame: Up to 24 months

    Sensitivity to change can be evaluated by calculating the effect size or the Minimum Clinically Important Difference, as statistics based on effect size provide direct information about the magnitude of the change, expressed as a variation, also used to calculate the Minimum Clinically Important Difference.

  4. Impact of skeletal-related events (SREs) on HRQoL (BOMET-QoL scores)

    Time frame: Up to 24 months

    The impact of skeletal-related events (SREs) on HRQoL (BOMET-QoL scores) will be measured by comparing patients who presented SREs with patients with without SREs.

  5. Relation between Eastern Cooperative Oncology Group (ECOG) and HRQoL (BOMET-QoL scores).

    Time frame: Up to 24 months

    ECOG: This scale consists of 5 levels (0 = No restrictions to carry out the activities normal, 1 = Restrictions to perform vigorous physical activities. It has the capacity to perform ambulation and light work, 2 = Ability to ambulate and perform personal care but not able to work. Capacity for standing and walking for> 50% of waking hours, 3 = Able to perform care limited personal; Incarcerated or restrained to be in a chair for> 50% of the hours of vigil, 4 = complete disability; he can not perform any personal care; it remains in bed or in a chair all the time, 5 = Death). In it the observer assesses the state of symptoms and the level of functioning in relation to ambulatory status and need for care. Patients with an Eastern Cooperative Oncology Group (ECOG) functional scale between 0-1 will obtain a higher score (better HRQoL) in the BOMET-QoL questionnaire.

  6. Correlation between visual analogue scale (VAS) score of pain and HRQoL (BOMET-QoL scores).

    Time frame: Up to 24 months

    At the baseline visit, patients who obtain higher scores on the Analogue Visual Pain Scale will obtain a lower score (worse HRQOL) in the BOMET-QoL questionnaire. Correlation between the BOMET-QoL scores and the pain VAS scores regarding whether it improves, stays the same or gets worse between the different study visits. VAS: 0 no pain - 10 unbearable pain

Sponsors and collaborators

Lead sponsor

Spanish Breast Cancer Research Group

Other

Collaborators

  • Novartis Pharmaceuticals

Registry information

Official study title

Prospective Study of the Utility of the BOMET-QOL Questionnaire Patients With Breast Cancer and Bone Metastasis

Acronym: MAbomet

Important dates

Study start
2007
Primary completion
2010
Study completion
2012
First posted
Feb 20, 2019
Registry last updated
Mar 6, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.